Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide
Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...
Gespeichert in:
Autoren: | , , , , , , , , , |
---|---|
格式: | Artikel |
語言: | 英语 |
出版: |
Philipps-Universität Marburg
2022
|
主題: | |
在線閱讀: | PDF-Volltext |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
PDF-Volltext索引號: |
urn:nbn:de:hebis:04-es2023-00588 |
---|---|
Publikationsdatum: |
2023-05-16 |
Quelle: |
Erstveröffentlichung: Otte, K.; Zhao, K.; Braun, M.; Neubauer, A.; Raifer, H.; Helmprobst, F.; Barrera, F.O.; Nimsky, C.; Bartsch, J.W.; Rusch, T. Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. Biomedicines 2022, 10, 2145. https://doi.org/10.3390/biomedicines10092145 |
Downloads: |
14 (2024), 44 (2023) |
Lizenz: |
https://creativecommons.org/licenses/by/4.0 |
Zugangs-URL: |
https://archiv.ub.uni-marburg.de/es/2023/0058 https://doi.org/10.3390/biomedicines10092145 |